Some cardiovascular therapeutics inhibit paraoxonase 1 (PON1) from human serum

European Journal of Pharmacology

Volumn 645, Issue 1-3, 2010, Pages 135-142

  Işgör, Mehmet Mustafa ^a   Beydemir, Şükrü ^a  

^a ATATÜRK UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Chromatography; Drugs; Inhibition; Paraoxonase

Indexed keywords

AMIODARONE; AMMONIUM SULFATE; ARYLDIALKYLPHOSPHATASE 1; CARDIOVASCULAR AGENT; DIGOXIN; DILTIAZEM; DOBUTAMINE; METHYLPREDNISOLONE; METOPROLOL TARTRATE; VERAPAMIL;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PURIFICATION; GEL FILTRATION CHROMATOGRAPHY; HUMAN; IC 50; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; PRECIPITATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; SERUM;

AMMONIUM SULFATE; ARYLDIALKYLPHOSPHATASE; CARDIOVASCULAR AGENTS; CHEMICAL PRECIPITATION; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; ENZYME INHIBITORS; HUMANS; SERUM;

EID: 77956191110     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.07.030     Document Type: Article

References (67)

1. Abbott C., Mackness M., Kumar S., Boulton A., Durrington P. Serum paraoxonase activity, concentration and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. Arterioscler. Thromb. Vasc. Biol. 1995, 15:1812-1818.
2. Alici H.A., Ekinci D., Beydemir S. Intravenous anesthetics inhibit human paraoxonase-1 (PON1) activity in vitro and in vivo. Clin. Biochem. 2008, 41:1384-1390.
3. Ates O., Azizi S., Alp H.H., Ki{dotless}zi{dotless}ltunc A., Beydemir S., Ci{dotless}ni{dotless}ci{dotless} E., Kocer I., Baykal O. Decreased serum paraoxonase 1 activity and increased homocysteine and malondialdehyde levels in age-related macular degeneration. Tohoku J. Exp. Med. 2009, 217:17-22.
4. Aviram M., Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic. Biol. Méd. 2004, 37:1304-1316.
5. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., La Du B.N. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions-a possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:1581-1590.
6. Aviram M., Rosenblat M., Bisgair C.L. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J. Clin. Invest. 1998, 101:2215-2257.
7. Aviram M., Rosenblat M., Billecke S., Erogul J., Sorenson R., Bisgaier C.L., Newton R.S., La Du B.N. Human serum paraoxonase (PON1) is inactivated by oxidised low density lipoprotein and reserved by antioxidants. Free Radic. Biol. Méd. 1999, 26:892-904.
8. Aviram M., Hardak E., Vaya J., Mahmood S., Milo S., Hoffman A., Billicke S., Draganov D., Rosenblat M. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxidesin human coronary and carotid atherosclerotic lesions. Circulation 2000, 101:2510-2517.
9. Beydemir S., Gulcin I. Effects of melatonin on carbonic anhydrase from human erythrocytes in vitro and from rat erythrocytes in vivo. J. Enzyme Inhib. Med. Chem. 2004, 19:193-197.
10. Beydemir S., Gulcin I., Kufrevioglu O.I., Ciftci M. Glucose 6-phosphate dehydrogenase: i{dotless}n vitro and in vivo effects of dantrolene sodium. Pol. J. Pharmacol. 2003, 55:787-792.
11. Blatter M.C., James R.W., Messmer S., Barja F., Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-85: identity of K-85 with paraoxonase. Eur. J. Biochem. 1993, 211:871-879.
12. Canales A., Sanchez-Muniz F.J. Paraoxonase something more than an enzyme?. Med. Clin. (Barc.) 2003, 121:537-548.
13. Chait A., Han C.Y., Oram J.F., Heinecke J.W. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease?. J. Lipid Res. 2005, 46:389-403.
14. Ciftci M., Beydemir S., Ekinci D. Effects of some drugs on enzyme activity of glucose 6-phosphate dehydrogenase from chicken erythrocytes in vitro. Asian J. Chem. 2008, 20:2189-2196.
15. Çiftci M., Beydemir Ş., Yi{dotless}lmaz H., Alti{dotless}kat S. Purification of glucose 6-phosphate dehydrogenase from Buffalo (Bubalus bubalis) erythrocytes and investigation of some kinetic properties. Protein Expr. Purif. 2003, 29:304-310.
16. Coban T.A., Beydemir S., Gulcin I., Ekinci D. Morphine inhibits erythrocyte carbonic anhydrase in vitro and in vivo. Biol. Pharm. Bull. 2007, 30:2257-2261.
17. Coban A., Beydemir S., Gulcin I., Ekinci D., Innocenti A., Vullo D., Supuran C.T. Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV. Bioorg. Med. Chem. 2009, 17:5791-5795.
18. Costa L.G., Li W.F., Richter R.J., Shih D.M., Lusis A., Furlong C.E. The role of paraoxonase (PON1) in the detoxification of organophosphates and its human polymorphism. Chem. Biol. Interact. 1999, 119-120:439-444.
19. Deakin S., James R. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Clin. Sci. 2004, 107:435-447.
20. Durrington P.N., Mackness B., Mackness M.I. Paraoxonase and atherosclerosis. Arterioscler. Thromb. Vasc. 2001, 21:473-480.
21. Ekinci D., Beydemir S. Effect of some analgesics on paraoxonase-1 purified from human serum. J. Enzyme Inhib. Med. Chem. 2009, 24:1034-1039.
22. Ekinci D., Beydemir S. Evaluation of the impacts of antibiotic drugs on PON 1; a major bioscavenger against cardiovascular diseases. Eur. J. Pharmacol. 2009, 617:84-89.
23. Ekinci D., Beydemir S. Purification of PON1 from human serum and assessment of enzyme kinetics against metal toxicity. Biol. Trace Elem. Res. 2009, 10.1007/s12011-009-8500-0.
24. Ekinci D., Beydemir S. Risk assessment of pesticides and fungicides for acid-base regulation and salt transport in rainbow trout tissues. Pestic. Biochem. Phys. 2010, 97:66-70.
25. Ekinci D., Beydemir S., Alim Z. Some drugs inhibit in vitro hydratase and esterase activities of human carbonic anhydrase-I and II. Pharmacol. Rep. 2007, 59:580-587.
26. Fonarow G.C. The global burden of atherosclerotic vascular disease. Nat. Clin. Pract. Cardiovasc. Med. 2007, 4:530-531.
27. Fortmann S.P., Haskell W.L., Williams P.T. Changes in plasma high density lipoprotein cholesterol after changes in cigarette use. Am. J. Epidemiol. 1986, 124:706-710.
28. Furlong C.E., Costa L.G., Haset C., Richter R.J., Sundstrom J.A., Adler D.A., Disteche C.M., Omiecinski C.J., Crabb J.W., Humbert R. Human and rabbit paraoxonases: purification, cloning, sequencing, mapping and role of polymorphism in organophosphate detoxification. Chem. Biol. Interact. 1993, 87:35-48.
29. Gaidukov L., Tawfik D.S. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Biochemistry 2005, 44:11843-11854.
30. Getz G.S., Reardon C.A. Paraoxonase, a cardioprotective enzyme: continuing issues. Curr. Opin. Lipidol. 2004, 15:261-267.
31. Gulcin I., Beydemir S., Coban T.A., Ekinci D. The inhibitory effect of dantrolene sodium and propofol on 6-phosphogluconate dehydrogenase from rat erythrocyte. Fresenius Environ. Bull. 2008, 17:1283-1287.
32. Gulcin I., Beydemir S., Coban T.A., Ekinci D. The inhibitory effect of ethanol on carbonic anhydrase isoenzymes: an in vivo and in vitro study. J. Enzyme Inhib. Med. Chem. 2008, 23:266-270.
33. Gürsu M.F., Özdin M. The i{dotless}nvestigation of levels of paraoxonase (PON 1) and malondialdehyde in smokers. Fi{dotless}rat Ti{dotless}p Derg. 2002, 7:732-737.
34. Harel M., Aharoni A.i, Gaidukov L., Brumshtein B., Khersonsky O., Meged R., Dvir H., Ravelli R.B., McCarthy A., Toker L., Silman I., Susman J.L., Tawfik D.S. Structure and evolution of the serum paraoxonase family of detoxifying and antiatherosclerotic enymes. Nat. Struct. Mol. Biol. 2004, 11:412-419.
35. Hennig B., Toborek M. Nutrition and endothelial cell function: implications in atherosclerosis. Nutr. Res. 2001, 21:279-293.
36. Josse D., Xie W., Renault F., Rochu D., Schopfer L.M., Mason P., Lockridge O. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities. Biochemistry 1999, 38:2816-2825.
37. Josse D., Lockridge O., Xie W., Bartels C.F., Schopfer L.M., Mason P. The active site of human paraoxonase (PON1). J. Appl. Toxicol. 2001, 21:7-11.
38. Kayaalp, O., 2000. Rasyonel Tedavi Yönünden Tibbi, Farmakoloji, Ankara. Hacettepe Tas yayincilik, 8th edn.
39. La Du B.N. Pharmo Genetics of Drug Metabolism 1992, Pergamon Press, New York, 51-91 pp.
40. La Du B.N., Aviram S., Billecke M., Navabc M., Primo-Parmoa S., Sorensona R.C., Standifordd T.J. On the physiological role(s) of the paraoxonases. Chem. Biol. Interact. 1999, 119-120:379-388.
41. Laplaud P., Dantoine T., Chapman J. Paraoxonase as a risk marker for cardiovascular disease: facts and hypotheses. Clin. Chem. Lab. Med. 1998, 36:431-441.
42. Leviev I., James R. Simvastatin increases plasma levels of the antioxidant enzyme paraoxonase by PON1 gene activation. Atherosclerosis 2000, 151:41.
43. Lineweaver H., Burk D. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 1934, 56:658-666.
44. Mackness M.I., Durrington P.N. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis 1995, 115:243-253.
45. Mackness M., Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important? Free Radic. Biol. Méd. 2004, 37:1317-1323.
46. Mackness M., Arrol S., Durrington P.N. Paraoxonase prevents accumulation of lipoperoxides in low-density-lipoprotein. FEBS Lett. 1991, 286:152-154.
47. Mackness B., Mackness M.I., Arrol S., Turkie W., Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998, 423:57-60.
48. Mackness M.I., Mackness B., Durrington P.N. Paraoxonase and coronary heart disease. Atheroscler. Suppl. 2002, 3:49-55.
49. Mackness M.I., Durrington P.N., Mackness B. Paraoxonase 1 activity, concentration and genotype in cardiovascular disease [Hyperlipidaemia and cardiovascular disease]. Curr. Opin. Lipidol. 2004, 15:399-404.
50. Malin R., Laaksonen R., Knuuti J., Janatuinen T., Vesalainen R., Nuutila P., Lehtimäki T. Paraoxonase genotype modifies the effect of pravastatin on high-density lipoprotein cholesterol. Pharmacogenetics 2001, 11:625-633.
51. Mazur A. An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates. J. Biol. Chem. 1946, 20:271-289.
52. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radical Biol. Med. 2005, 38:153-163.
53. Nishio E., Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem. Biophys. Res. Commun. 1997, 236:289-293.
54. Orlandi A., Bochaton-Piallat M.L., Gabbiani G., Spagnoli L.G. Aging, smooth muscle cells and vascular pathobiology: i{dotless}mplications for atherosclerosis. Atherosclerosis 2006, 188:221-230.
55. Pla A., Rodrigo L., Hernandez A.F., Gil Lopez F.O. Effect of metal ions and calcium on purified PON1 and PON3 from rat liver. Chem. Biol. Interact. 2007, 167:63-70.
56. Primo-Parmo S.L., Sorenson R.S., Teiber J., La Du B.N. The human serum paraoxonase/arylesterase gen (PON1) is one member of a multigene family. Genomics 1996, 33:498-507.
57. Rosenblat M., Karry R., Aviram M. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: Relevance to diabetes. Atherosclerosis 2006, 187:74-81.
58. Rozenberg O., Shih S.D., Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis 2005, 181:9-18.
59. Rye K.A., Clay M.A., Barter P.J. Remodelling of high-density lipoproteins by plasma factors. Atherosclerosis 1999, 145:227-238.
60. Scheffler E., Huber L., Fruhbis J., Schulz I., Ziegler R., Dresel H.A. Alteration of plasma low density lipoprotein from smokers. Atherosclerosis 1990, 82:261-265.
61. Senturk M., Talaz O., Ekinci D., Cavdar H., Kufrevioglu O.I. In vitro inhibition of human erythrocyte glutathione reductase by some new organic nitrates. Bioorg. Med. Chem. 2009, 19:3661-3663.
62. Sinan S., Kockar F., Arslan O. Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglycoside derived antibiotics. Biochimie 2006, 88:565-574.
63. Tomas M., Senti M., Garcia-Faria F., Vila J., Torrents A., Covas M., Marrugat J. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients. Arterioscler. Thromb. Vasc. 2000, 20:2113-2119.
64. Tsompanidi E.M., Brinkmeier M.S., Fotiadou E.H., Giakoumi S.M., Kypreos K.E. HDL biogenesis and functions: role of HDL quality and quantity in atherosclerosis. Atherosclerosis 2009, 10.1016/j.atherosclerosis.2009.05.034.
65. Watson A., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman A.M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J. Clin. Invest. 1995, 96:2882-2891.
66. Yi{dotless}lmaz H., Çiftci M., Beydemir S., Bakan E. Purification of glucose 6-phosphate dehydrogenase from chicken erythrocytes. Investigation of some kinetic properties. Prep. Biochem. Biotechnol. 2002, 32:287-301.
67. Zieskea A.W., McMahanb C.A., McGill H.C., Hommaa S., Takeia H., Malcoma G.T., Tracya R.E., Strong J.P. Smoking is associated with advanced coronary atherosclerosis in youth. Atherosclerosis 2005, 180:87-92.